Günay Semra, Alan Ömür, Yalçın Orhan, Türkmen Aygen, Dizdar Nihal
Clinic of Breast and Endocrin Surgery, Ministry of Health Okmeydanı Training and Research Hospital, İstanbul, Turkey.
Clinic of Oncology, Ministry of Health Okmeydanı Training and Research Hospital, İstanbul, Turkey.
Ulus Cerrahi Derg. 2015 Jun 24;32(1):30-6. doi: 10.5152/UCD.2015.2952. eCollection 2016.
To present our experience since November 2013, and case selection criteria for intraoperative boost radiotherapy (IObRT) that significantly reduces the local recurrence rate after breast conserving surgery in patients with breast cancer.
Patients who were suitable for IObRT were identified within the group of patients who were selected for breast conserving surgery at our breast council. A MOBETRON (mobile linear accelerator for IObRT) was used for IObRt during surgery.
Patients younger than 60 years old with <3 cm invasive ductal cancer in one focus (or two foci within 2 cm), with a histologic grade of 2-3, and a high possibility of local recurrence were admitted for IObRT application. Informed consent was obtained from all participants. Lumpectomy and sentinel lymph node biopsy was performed and advancement flaps were prepared according to the size and inclination of the conus following evaluation of tumor size and surgical margins by pathology. Distance to the thoracic wall was measured, and a radiation oncologist and radiation physicist calculated the required dose. Anesthesia was regulated with slower ventilation frequency, without causing hypoxia. The skin and incision edges were protected, the field was radiated (with 6 MeV electron beam of 10 Gy) and the incision was closed. In our cases, there were no major postoperative surgical or early radiotherapy related complications.
The completion of another stage of local therapy with IObRT during surgery positively effects sequencing of other treatments like chemotherapy, hormonotherapy and radiotherapy, if required. IObRT increases disease free and overall survival, as well as quality of life in breast cancer patients.
介绍我们自2013年11月以来的经验,以及术中追加放疗(IObRT)的病例选择标准,该标准可显著降低乳腺癌保乳手术后的局部复发率。
在我们乳腺委员会选择进行保乳手术的患者群体中,确定适合IObRT的患者。手术期间使用MOBETRON(用于IObRT的移动直线加速器)进行IObRt。
年龄小于60岁、单灶(或两个病灶相距2 cm以内)浸润性导管癌小于3 cm、组织学分级为2 - 3级且局部复发可能性高的患者被纳入IObRT应用。所有参与者均获得知情同意。进行了肿块切除术和前哨淋巴结活检,并在病理评估肿瘤大小和手术切缘后,根据圆锥体的大小和倾斜度制备推进皮瓣。测量到胸壁的距离,放射肿瘤学家和放射物理学家计算所需剂量。通过降低通气频率调节麻醉,不引起缺氧。保护皮肤和切口边缘,进行照射(使用10 Gy的6 MeV电子束),然后关闭切口。在我们的病例中,没有出现重大的术后手术或早期放疗相关并发症。
手术期间通过IObRT完成局部治疗的另一个阶段,如果需要,对化疗、激素治疗和放疗等其他治疗的顺序有积极影响。IObRT可提高乳腺癌患者的无病生存率和总生存率,以及生活质量。